Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19

We applied a set of in silico and in vitro assays, compliant with the Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm, to assess the risk of chloroquine (CLQ) or hydroxychloroquine (OH‐CLQ)‐mediated QT prolongation and Torsades de Pointes (TdP), alone and combined with erythromycin (ERT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Delaunois, Annie, Abernathy, Matthew, Anderson, Warren D., Beattie, Kylie A., Chaudhary, Khuram W., Coulot, Julie, Gryshkova, Vitalina, Hebeisen, Simon, Holbrook, Mark, Kramer, James, Kuryshev, Yuri, Leishman, Derek, Lushbough, Isabel, Passini, Elisa, Redfern, Will S., Rodriguez, Blanca, Rossman, Eric I., Trovato, Cristian, Wu, Caiyun, Valentin, Jean‐Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014548/
https://www.ncbi.nlm.nih.gov/pubmed/33620150
http://dx.doi.org/10.1111/cts.13011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014548/
https://www.ncbi.nlm.nih.gov/pubmed/33620150
http://dx.doi.org/10.1111/cts.13011

Ejemplares similares